Global Conference on Regulatory Science (October 11, 2022)
LEARN MORE
Improving the Process of Therapeutic Development
Harvard, MIT, and the FDA have partnered to create a center focused on regulatory science, bringing together a range of scientific disciplines that are applied to assess the quality, safety and efficacy of medicinal products and inform regulatory decision-making throughout the lifecycle of a medicine. Working across academia, industry, and government institutions, the Center promotes regulatory science through research and education programs, uniting stakeholders under a common mission: promoting optimal patient health outcomes through biomedical innovation and the availability of safe and effective diagnostics and treatments.
Featured Publications
The Regulatory Science Fellowship Program
Our fellowship program is affiliated with the FDA and focuses on training the next generation of regulatory science researchers. Learn more about the research our fellows are conducting or explore opportunities and how to get involved in our program.
News, Events, & Updates
Twitter @Harvardmit_CRS
Out today in JAMA, @SusmithaWunnava, a fellow in my lab, led this great foundational work in establishing the evidence gap in pediatric medical devices. @ftbourgeois @HarvardMIT_CRS https://twitter.com/JAMA_current/status/1557079264021082112
Relative to adult use, few high-risk cardiovascular devices have been approved for pediatric use and less than half of devices with pediatric labeling were approved on the basis of clinical trials that included children. https://ja.ma/3vQhvbT #ResearchLetter
"Trends in Remote Patient Monitoring Use in Traditional Medicare" co-authored by CRS Faculty @arieldora 🧵⬇️
Hot 🔥and fresh 👟 in this week's @JAMAInternalMed with @MitchellTang1 @carter_nakamoto & @Ateevm: "Trends in Remote Patient Monitoring Use in Traditional Medicare"
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2794655?guestAccessKey=5e6c4671-4bd8-48e2-bf9c-83898250648e&utm_source=jps&utm_medium=email&utm_campaign=author_alert-jamanetwork&utm_content=author-author_engagement&utm_term=1m
Don't miss publications from CRS members and faculty, events, and regulatory science news in this week's CRS newsletter.🔗https://bit.ly/3bsSRHt Subscribe here ➡️https://bit.ly/crsnewsletter
My PhD dissertation was an honorable mention for the 2022 Best Dissertation Award at the U of MN! I was runner-up in the Biological and Medical Sciences category and don't even understand the title of the winner in that category, so that's pretty cool.
https://grad.umn.edu/news-events/news-overview/announcing-2022-graduate-school-best-dissertation-award-winners
Read "New legislation to promote paediatric studies for new cancer medicines" by @thomasmd and CRS Co-Director @ftbourgeois here: https://bit.ly/3PIcmtU
New study by our resident @thomasmd in @TheLancetOncol on impact of new law on pediatric cancer trials with @ftbourgeois.
🔗:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00376-X/fulltext